- Selexis SUREvariant screening
Cells, used as factories producing drugs, are critically important instruments employed in almost every aspect of biologics drug discovery, development and manufacturing. The Selexis SUREtechnology Platform™, in addition to significantly improving manufacturing cell line development, has been adapted to speed identification and development of novel biotherapeutics while still reducing the time and costs associated with entering pre-IND enabling studies.
Selexis’ SUREvariant screening™ accelerates and improves outcomes from displayed library selection campaigns by reducing the time and the number of steps to identify potential lead candidates. The SUREvariant screening™ platform used at Selexis can generate panels of up to 500 CHO-M cell pools (SUREpools™), each expressing different protein variants. Typical expression levels in the supernatants (SUREnatants™) for MAbs vary between 50-500 mg/L. The SUREnatants™ containing the recombinant proteins expressed with mammalian post-translational modifications can be readily assessed for activity. Subsequently, Selexis SUREpools™ top candidates can be banked (stored) and then reused for further assays. The top SUREpool™ candidate is transferred to the Selexis’ SURE Cell line™ Development platform to generate a high producing clonal cell line ready for cGMP manufacturing. This procedure ensures perfect match between preclinical and clinical material notably including glycan analysis.The entire process from SUREvariant screening™ to the clonal cell line can be as short as 14 weeks. Selexis SUREvariant screening™ can reduce your development costs by over $500,000 per clinical candidate!
- Weeds out candidates that cannot be easily expressed in mammalian cells
- Determines the values of mammalian protein modifications early
- Ensures a steady supply of preclinical material
- Significantly reduces development time and costs by eliminating the need for repeated transient transfections
- Reduces manufacturing issues through early selection of candidates that are readily expressed
- Promotes faster, more informed decision-making
- Typically saves ≥6 months between initiation of the screen and completion of master cell banking
- Typically reduces costs by over $500,000 per clinical candidate
Thus, Selexis technologies and services are increasing the efficiency at which new lead compounds can be identified and manufactured across the entire biopharmaceutical industry.
Clients are able to CHOose from 2 options for obtaining preclinical material from the SUREvariant screening™ services:
Selexis SUREnatants™
- Transfections carried out in 6-well plates
- Milligram quantities of protein available for testing (up to 500 ml culture)
- Supernatant transfer in 3 weeks
- Transferred under simple MTA
Selexis SUREpools™
- Cell pools in 3 weeks (from transfection)
- Typical protein expression levels at mg quantities.
- Transferred under license
